Abstract
The outbreak and pandemic of SARS-CoV-2 in 2019 has caused a severe public health burden and will challenge global health for the future. The discovery and mechanistic investigation of drugs against Coronavirus disease 2019 (COVID-19) is in deadly demand. The paper published by Li and colleagues proposed the hypothesis that vitamin C combined with glycyrrhizic acid in treating COVID-19 and its mechanistic investigation was performed by a database-based network pharmacology. In this letter, we present critical comments on the limitations and insufficiencies involved, from both the perspective of network pharmacology and current evidence on COVID-19.
Keywords: COVID-19; glycyrrhizic acid; network pharmacology; vitamin C.
【저자키워드】 COVID-19, Vitamin C, network pharmacology, glycyrrhizic acid, 【초록키워드】 coronavirus disease, public health, SARS-CoV-2, Coronavirus disease 2019, pandemic, Vitamin C, network pharmacology, drug, global health, glycyrrhizic acid, Health, outbreak, Critical, Evidence, Hypothesis, paper, Perspective, limitation, treating COVID-19, caused, involved, was performed, 【제목키워드】 Drug repurposing, glycyrrhizic acid,